Question Bank › The knock on the company is going stale

The knock on the company is going stale

The knock on the company is going stale: this quarter's own facts cut against the standing doubt

Calls Tested
287
Answered YES
68
Hit Rate
23.7%
rare by design

Huntington Ingalls Industries, Inc. (HII) — this company's answers

NO on the Q1 2017 call 2017-05-04 C
The model's full reasoning — Q1 2017 call → NO我们根据提供的财报电话会议记录,需要判断是否存在一个明确的、公司特定的疑虑,并且本季度的实际运营证据是否明显反驳了该疑虑。 首先,寻找疑虑。在电话会议中,分析师和公司管理层讨论了多个话题。关键疑虑可能包括:对Westinghouse破产的敞口(技术解决方案部门),对政府预算/订单的依赖,LPD项目后的生产缺口,以及技术解决方案部门的盈利能力。但我们需要一个“standing doubt”——即长期存在的、公司特定的疑虑,在电话会议中明显可见。 从记录中,分析师反复询问关于技术解决方案部门的利润率(George Shapiro问及该部门收入下降),以及关于未来订单(如LPD 29、LXR、哥伦比亚级等)的可持续性。管理层也承认了这些担忧,例如Mike Petters提到“我们仍然认为海军业务全年持平,回报率9%-10%”,并讨论了LPD 29作为桥梁的重要性。但这是否构成一个明确的“standing doubt”?可能更具体的是关于技术解决方案部门的盈利能力,因为该部门本季度亏损(由于Westinghouse储备),但管理层表示预期低个位数利润率。然而,分析师的问题更多是询问细节,而非表达怀疑。 另一个可能的疑虑是公司对政府预算的依赖,但这是行业普遍现象,并非公司特定。 再考虑“本季度实际运营证据是否反驳了疑虑”。例如,关于LPD项目后的生产缺口,本季度有LPD 29获得资金,这确实反驳了“生产缺口”的担忧。但这是否是“本季度实际发生的”事件?是的,LPD 29在2017财年预算中获得全额资金,这是本季度发生的。但管理层在电话会议中提到了这一点,并说“我们很高兴2017年的结果”。然而,这更多是预算批准,而非公司运营本身。 另一个疑虑可能是关于技术解决方案部门的盈利能力,但本季度由于Westinghouse储备而亏损,这实际上确认了疑虑,而非反驳。 再考虑关于航空母舰建造的疑虑?没有明显。 或许疑虑是“公司能否维持订单流”,但管理层在电话会议中讨论了多个项目,但并没有一个明确的“standing doubt”被反复提及。 仔细阅读:分析师David Strauss问及风险退休里程碑,管理层回答“我们仍然认为海军业务持平,9%-10%回报率”。这似乎是对业绩的确认,而非疑虑。 分析师Gautam Khanna问及CVN 79的风险退休,管理层说“没有重大事项”。这也不是疑虑。 分析师Rob Spingarn问及资本支出和未来投资,管理层回答“我们正在观察2018年预算”。这更多是前瞻性。 分析师George Shapiro问及技术解决方案部门收入下降,管理层解释是季节性和一次性因素。这似乎是在解释,而非反驳疑虑。 或许疑虑是“对Westinghouse的敞口”,但管理层已经计提了储备,并说将继续工作并预期获得付款。这算反驳吗?但这是对一次性事件的回应,而非长期疑虑。 再考虑“公司依赖单一客户(美国海军)”,但这是行业特性,并非公司特定。 也许疑虑是“LPD项目后的生产缺口”,但本季度LPD 29获得资金,这确实反驳了该疑虑。但这是否是“本季度实际发生的”?是的,预算在4月通过,本季度内。管理层在电话会议中提到了这一点。但这是否是“运营证据”?预算批准是外部事件,但公司确实获得了订单。 然而,问题要求“本季度自身的运营证据”,即公司实际做了什么。LPD 29的拨款是政府行为,但公司获得了合同,这算运营证据吗?可能算。 但更关键的是,这个疑虑是否在电话会议中明显可见?管理层在回答中提到了“LPD 29是桥梁”,表明他们知道这个担忧。分析师也问过关于LPD项目后的情况。 但问题要求“一个明确的、公司特定的疑虑”,并且“本季度的实际运营证据明显反驳它”。我认为LPD 29的拨款确实反驳了“生产缺口”的担忧,但这是否是“standing doubt”?在电话会议中,管理层多次提到需要LXR来填补缺口,但LPD 29是第一步。然而,这个疑虑可能不是“standing”,而是当前讨论的。 另一个可能的疑虑是“技术解决方案部门的盈利能力”,但本季度亏损,所以没有反驳。 或许疑虑是“公司能否维持利润率”,但管理层说9-10%是目标,本季度海军业务表现良好。 再考虑“Westinghouse破产”的影响,但这是新事件,不是standing。 我认为没有明确的“standing doubt”被反复提及。分析师的问题更多是询问细节,而非表达怀疑。管理层也没有直接回应一个长期存在的疑虑。 因此,答案应为NO。 但让我们再确认:是否有分析师说“我担心...”?没有。管理层是否说“投资者担心...”?没有。 所以,我认为没有明确的公司特定疑虑。 因此,答案NO。

← Back to the full HII analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: Reading this call as a whole, can you identify ONE well-defined DOUBT that has clearly been weighing on how this company is perceived — a standing knock evident from the transcript itself, such as skepticism that its losses will ever end, that its main product or model will find repeat demand, that its legacy business's decline will swamp everything else, that it depends too heavily on one customer, market, or financing source, or another comparable company-specific concern — AND does the CURRENT PERIOD'S OWN OPERATING EVIDENCE, as recounted by management, move clearly AGAINST that doubt? Answer YES when BOTH halves come through in the transcript, in whatever form fits the business: (1) A STANDING, COMPANY-SPECIFIC DOUBT IS VISIBLE ON THE CALL. The transcript itself shows that a particular concern has hung over this company — through analysts returning to it, management acknowledging what skeptics or investors have worried about, or management plainly addressing a question it knows the audience carries (can this business make money, will anyone buy this at scale, will the decline stop, can they fund themselves, will the big customer stay). The doubt must be specific to this company's situation, not generic macro gloom, and must read as something that predates this quarter rather than arising on this call. (2) THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT. Management recounts concrete things that actually happened in the recent period — actual orders, customers returning or expanding, real revenue or volumes where there had been little, losses narrowing because of how the business itself is now running, the doubted product performing in real use, the feared departure or decline not occurring while something better did — described with enough operating substance that the contradiction rests on observed events rather than on reassurance, plans, or projections. The evidence need not fully settle the doubt; what matters is that the current period's facts point the other way and management engages the doubt with those facts. Answer NO if no company-specific doubt is discernible — an ordinarily healthy company reporting a routine quarter. NO if the doubt exists but management answers it mainly with confidence, vision, targets, or hoped-for improvements rather than with things that already happened. NO if the period's evidence actually confirms the doubt (the losses widened, the decline continued, the customer left) and management is excusing it. NO if the contrary evidence is a one-time item, an asset sale, a financing, or something management itself treats as non-recurring rather than the business operating differently. NO if the doubt and the evidence never connect — strong facts reported on one topic while the standing concern sits elsewhere untouched. NO if the doubt appears only as boilerplate risk language or an analyst aside that management never engages. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GL Globe Life Inc. Q1 2024 2024-04-23 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
PFE Pfizer Inc. Q4 2023 2024-01-30 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
BZUN Baozun Inc. Q2 2023 2023-08-28 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
BXSL Blackstone Secured Lending Fund Q1 2023 2023-05-10 A
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
CLSD Clearside Biomedical, Inc. Q3 2022 2022-11-09 C
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
SE Sea Limited Q1 2022 2022-05-17 F
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
WYY WidePoint Corporation Q3 2016 2016-11-09 D
ULBI Ultralife Corporation Q3 2016 2016-10-29 C+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GES Guess?, Inc. Q1 2017 2016-05-25 F
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.

More from the question bank

Acted like it's already biggerBetting on a claim they haven't proven yetMoney already collected for work not yet donNew faces on the callThe streak is aliveCommitted past the numbersAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.